Post-surgical intestinal dysbiosis: use of an innovative mixture (Lactobacillus plantarum LP01, Lactobacillus lactis subspecies cremoris LLC02, Lactobacillus delbrueckii LDD01).
- 2019-07-10
- Acta bio-medica : Atenei Parmensis 90(7-S)
- Luigi Bonavina
- Andrea Arini
- Leonardo Ficano
- Donato Iannuzziello
- Luigi Pasquale
- Salvo Emanuele Aragona
- Giorgio Ciprandi
- Italian Study Group On Digestive Disorders
- PubMed: 31292422
- DOI: 10.23750/abm.v90i7-s.8651
Study Design
- Type
- Clinical Trial
- Population
- 612 outpatients (344 males and 268 females, mean age 58 years) undergoing digestive surgery
- Methods
- evaluated the efficacy and safety of Abincol®, an oral nutraceutical containing a probiotic mixture with Lactobacillus plantarum LP01 (1 billion of living cells), Lactobacillus lactis subspecies cremoris LLC02 (800 millions of living cells), and Lactobacillus delbrueckii LDD01 (200 millions of living cells); patients took 1 stick/daily for 8 weeks
Abdominal surgery represents a high risk for hospital-acquired infections and complication that may compromise the surgery outcome. Patients with recent abdominal surgery have an intestinal dysbiosis. There is evidence that probiotics may counterbalance the impaired microbiota. Therefore, the current survey evaluated the efficacy and safety of Abincol®, an oral nutraceutical containing a probiotic mixture with Lactobacillus plantarum LP01 (1 billion of living cells), Lactobacillus lactis subspecies cremoris LLC02 (800 millions of living cells), and Lactobacillus delbrueckii LDD01 (200 millions of living cells), in 612 outpatients (344 males and 268 females, mean age 58 years) undergoing digestive surgery. Patients took 1 stick/daily for 8 weeks. Abincol® significantly diminished the presence and the severity of intestinal symptoms and improved stool form. In conclusion, the current survey suggests that Abincol® may be considered an effective and safe therapeutic option in the management of patients undergoing digestivesurgery.
Research Insights
and improved stool form
- Effect
- Beneficial
- Effect size
- Moderate
- Dose
- 1 billion living cells/day
Abincol® significantly diminished the presence and the severity of intestinal symptoms
- Effect
- Beneficial
- Effect size
- Moderate
- Dose
- 1 billion living cells/day
Adverse Events Reported
Abincol® may be considered an effective and safe therapeutic option in the management of patients undergoing digestive surgery.
- Finding
- Reported